Company / Total Debt
Akebia Therapeutics, Inc. Total Debt History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$48.3M
FY2025
5-year range
$0 / $66.1M
FY2021-FY2025
Trend
+24.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Debt has fluctuated over the past 7 years, ranging from $0 in FY2021 to $96M in FY2020.
Based on SEC 10-K filings.
$48M in FY2025 with a 5-year CAGR of -12.9%.
Increased from $35M to $48M over the past 2 years.
Total Debt over time
Growth rates
- 3-Year CAGR
- -10.0%
- 5-Year CAGR
- -12.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -12.9%, indicating a declining trend.
- In FY2025, total debt increased 24.7% year-over-year.
- Peak total debt was recorded in FY2020.
- Lowest total debt in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $48.3M | +24.7% |
| FY2024 | $38.7M | +11.6% |
| FY2023 | $34.7M | -47.5% |
| FY2022 | $66.1M | - |
| FY2021 | $0 | -100.0% |
| FY2020 | $96.4M | +27.1% |
| FY2019 | $75.8M | - |
| FY2018 | - | - |
| FY2015 | - | - |
| FY2014 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026